EMERYVILLE, Calif., Nov. 16 /PRNewswire/ -- KineMed, Inc., a platform- based indications discovery and development drug company, presented breakthrough results today from a new product program at the Society for Neuroscience meeting being held in Washington, DC. In a poster presentation entitled, "In Vivo Heavy Water (2H2O) Labeling: A Novel Method For Measuring Hippocampal Cell Proliferation And Neurogenesis," the Company described a sensitive, high-throughput assay for identifying agents that stimulate the formation of new brain cells (neurogenesis) and, thus, are potentially anti- depressant drugs. Data will be presented validating the neurogenic effects of known anti-depressants and the discovery of several previously unrecognized neurogenic drugs.
The presentation information is as follows: Date: Wednesday, November 16th, 2005 Time: 1:00-2:00 pm, Eastern Standard Time Location: Washington Convention Center Hall A-C Title of Presentation: "In Vivo Heavy Water (2H2O) Labeling: A Novel Method For Measuring Hippocampal Cell Proliferation And Neurogenesis," the presentation will take place during the session entitled, Animal models of depression: Neurogenesis and Neurotrophic Factors II, Poster # 1024.9).
David Fineman, President and CEO of KineMed, commented, "This is the first time that a high-throughput quantitative biomarker has been developed for neurogenesis. This tool has a unique ability to provide granular and insightful in vivo data required for screening and selecting novel neurogenic agents which will enable the next generation of drugs that treat depression, stroke, traumatic brain injury and other neurological disorders."
KineMed KineMarker(TM) Product Programs in Neuroscience
KineMed's proprietary in vivo KineMarker(TM) assays provide new, sensitive and high-throughput measures of several key pathways involved in the pathogenesis and treatment of neurodegenerative and psychiatric disorders. These assays can be used in clinical as well as pre-clinical settings.
KineMed's neurogenesis KineMarker(TM) is much more sensitive, reproducible, high-throughput than traditional methods, such as BrdU labeling.
Other areas of neurobiology where KineMed has active discovery programs include multiple sclerosis (myelination), Alzheimer's disease (neuroinflammation and amyloid precursor protein kinetics), memory and learning (brain microtubule dynamics) and ALS (motor neuron disease).
About KineMed, Inc.
KineMed, Inc. provides a proprietary set of tools for measuring the dynamics of molecular and cellular response to drugs in the intact organism, both in animals and humans. KineMed's technology is ideally suited to enable the discovery of entirely new, unanticipated uses for compounds (an approach called repurposing or repositioning) by screening for activity in vivo across a wide variety of disease states. The breadth of therapeutic targets covered by KineMarker(TM) assays allows high-throughput screening in conditions beyond those typically evaluated. KineMed's technology expedites the drug development process and provides real-time insight into conditions including metabolic disorders, cancer, and diseases of inflammation and neurodegeneration.
For further information about KineMed, please visit: http://www.kinemed.com
KineMed, Inc.CONTACT: Lisa Misell, Ph.D., Vice President of Business Development, ofKineMed, +1-510-655-6525, ext. 117; or Media: Justin Jackson, of BurnsMcClellan, +1-212-213-0006, jjackson@burnsmc.com, for KineMed, Inc.
Web site: http://www.kinemed.com/
